NO20021270L - Formuleringer for parenteral bruk av estramustinfosfat og sulfoalkyleter-cyklodekstriner - Google Patents

Formuleringer for parenteral bruk av estramustinfosfat og sulfoalkyleter-cyklodekstriner

Info

Publication number
NO20021270L
NO20021270L NO20021270A NO20021270A NO20021270L NO 20021270 L NO20021270 L NO 20021270L NO 20021270 A NO20021270 A NO 20021270A NO 20021270 A NO20021270 A NO 20021270A NO 20021270 L NO20021270 L NO 20021270L
Authority
NO
Norway
Prior art keywords
formulations
parenteral use
estramustine phosphate
sulfoalkyl ether
ether cyclodextrins
Prior art date
Application number
NO20021270A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021270D0 (no
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20021270D0 publication Critical patent/NO20021270D0/no
Publication of NO20021270L publication Critical patent/NO20021270L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20021270A 1999-09-16 2002-03-14 Formuleringer for parenteral bruk av estramustinfosfat og sulfoalkyleter-cyklodekstriner NO20021270L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921958.6A GB9921958D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
PCT/EP2000/007680 WO2001019339A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Publications (2)

Publication Number Publication Date
NO20021270D0 NO20021270D0 (no) 2002-03-14
NO20021270L true NO20021270L (no) 2002-03-14

Family

ID=10861068

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021270A NO20021270L (no) 1999-09-16 2002-03-14 Formuleringer for parenteral bruk av estramustinfosfat og sulfoalkyleter-cyklodekstriner

Country Status (19)

Country Link
US (1) US6730664B1 (xx)
EP (1) EP1212041A1 (xx)
JP (1) JP2003509356A (xx)
KR (1) KR20020059401A (xx)
CN (1) CN1374857A (xx)
AU (1) AU777684B2 (xx)
BR (1) BR0014062A (xx)
CA (1) CA2385065A1 (xx)
CZ (1) CZ2002944A3 (xx)
EA (1) EA003936B1 (xx)
GB (1) GB9921958D0 (xx)
HU (1) HUP0300185A3 (xx)
IL (1) IL148408A0 (xx)
MX (1) MXPA02002855A (xx)
NO (1) NO20021270L (xx)
PL (1) PL356026A1 (xx)
SK (1) SK3462002A3 (xx)
WO (1) WO2001019339A1 (xx)
ZA (1) ZA200201744B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
CA2631014C (en) * 2005-11-28 2015-04-28 Vernon D. Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2024074600A1 (en) * 2022-10-05 2024-04-11 Institut Gustave Roussy An oral liquid composition of vinorelbine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523035A (en) * 1976-03-10 1978-08-31 Leo Ab Derivatives of estradiol - 17 - dihydrogen phosphates
JPS59108800A (ja) 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
EA200200370A1 (ru) 2002-10-31
GB9921958D0 (en) 1999-11-17
EA003936B1 (ru) 2003-10-30
NO20021270D0 (no) 2002-03-14
JP2003509356A (ja) 2003-03-11
KR20020059401A (ko) 2002-07-12
EP1212041A1 (en) 2002-06-12
SK3462002A3 (en) 2002-08-06
MXPA02002855A (es) 2003-07-21
AU6993900A (en) 2001-04-17
HUP0300185A2 (en) 2003-05-28
CN1374857A (zh) 2002-10-16
BR0014062A (pt) 2002-12-31
PL356026A1 (en) 2004-05-31
CA2385065A1 (en) 2001-03-22
US6730664B1 (en) 2004-05-04
AU777684B2 (en) 2004-10-28
CZ2002944A3 (cs) 2002-08-14
IL148408A0 (en) 2002-09-12
HUP0300185A3 (en) 2007-02-28
WO2001019339A1 (en) 2001-03-22
ZA200201744B (en) 2004-01-28

Similar Documents

Publication Publication Date Title
HUP0202477A3 (en) Use of phthalazine derivatives
PL354623A1 (en) Manufacture of polyglutamate-therapeutic agent conjugates
GB2374100B (en) Underreamer and method of use
GB9926956D0 (en) Amplifier
HUP0200787A2 (hu) Eljárás és berendezés molekuláris kölcsönhatások meghatározása
AU3064699A (en) Dynamic orthopedic braces
AU2515000A (en) Pipe structure and method of manufacture
DE69938232D1 (de) Ausweitbarer stent
IL186954A0 (en) 4-phenyl-1-piperazinyl,-piperidinyl and tetrahydropyridyl derivatives
NO20013585L (no) Kompleks av ras-farnesyltransferaseinhibitor og sulfobutyleter-7-<beta>-cyklodekstrin eller 2-hydroksypropyl-<beta>-cyklodekstrin og fremgangsmate
NO20020362L (no) Fremgangsmåte og sammensetninger for utspyling av sulfider i borfluid
NO20015542D0 (no) Fremgangsmåte for fremstilling og anvendelse av N- desmetylzopikloner
GB9928355D0 (en) Amplifier
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
AU1556501A (en) Differential amplifier
NO20021270D0 (no) Formuleringer for parenteral bruk av estramustinfosfat og sulfoalkyleter-cyklodekstriner
GB9913548D0 (en) Amplifier
DE69917739D1 (de) Expandierbarer stent
PL334333A1 (en) Method of obtaining cyclodextrin
NO20020631D0 (no) Formuleringer for parenteral bruk av estramustinfosfat og albumin
DE60018744D1 (de) Komplex von Eletriptan und Sulfobutylether-cyclodextrin und dessen Verwendung zur Behandlung von Migräne
AU7068400A (en) Devices and methods for the generation of voltage potential
NO20021306L (no) Formuleringer for parenteral bruk av estramustinfosfat med forbedrede formakologiske egenskaper
NO20022446D0 (no) Etere av O-desmetyl-venlafaxine

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application